Benzinga··Vandana SinghBiogen Rallies on Pipeline Progress Despite Leqembi Review Delay
Biogen shares rise 1.06% to $193.40 despite FDA extending Leqembi review to August 2026, offset by $5.6B Apellis acquisition and Spinraza approval momentum.
APLSBIIBbiotechApellis Pharmaceuticals